Press Releases September 1, 2026 08:00 AM

Septerna to Participate in Upcoming Investor Conferences

Septerna to Present at Key Healthcare Investor Conferences in September 2026

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
SEPN

Septerna, Inc., a clinical-stage biotech focusing on GPCR drug discovery, announced management's participation in two major healthcare investor conferences in September 2026, including live webcasts. The company highlights its proprietary technology platform and diverse pipeline targeting endocrinology, immunology, inflammation, and metabolic diseases.

Septerna to Participate in Upcoming Investor Conferences
SEPN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Septerna's management will present at the Wells Fargo 21st Annual Healthcare Conference and Cantor Global Healthcare Conference 2026.
  • The company utilizes a proprietary Native Complex Platform to advance novel oral small molecule drug candidates targeting multiple therapeutic areas.
  • The investor presentations aim to provide updates on pipeline progress and strategic initiatives, enhancing investor engagement.

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences in September:

Wells Fargo 21st Annual Healthcare Conference
Fireside chat on Tuesday, September 8, 2026, at 8:00 a.m. ET

Cantor Global Healthcare Conference 2026
Fireside chat on Thursday, September 10, 2026, at 11:30 a.m. ET

A live webcast of each presentation will be available in the investors section of the company’s website at www.septerna.com. The webcasts will be archived for at least 30 days following the presentation.

About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.

Investor Contact:
Renee Leck, THRUST
[email protected]

Media Contact:
Carly Scaduto, THRUST
[email protected]


Risks

  • Clinical-stage status means products are subject to regulatory approval risks which may delay or prevent commercialization.
  • Competition in GPCR drug discovery and therapeutics could impact market share and development success.
  • Dependence on ongoing funding and partnerships is critical for advancing pipeline and sustaining operations.

More from Press Releases

Zhihu Inc. Announces Proposed Subscription in AI-Focused Investment Fund Sep 6, 2026 Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call Sep 6, 2026 Verizon Waives Charges for Hurricane Lowell, Prepares Network in Hawai'i Sep 5, 2026 Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen Sep 4, 2026 Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Increase in August 2026 of 0.5% Compared to 2025 Sep 4, 2026